| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 91.08 | 23.8% |
| Total Income | 91.59 | 23.9% |
| Expenditure | 124.61 | 8.4% |
| PBT | -33.02 | 110.8% |
| Net Profit | -33.03 | 105.4% |
| OPM | -12.06% | 16.68pp |
| NPM | -36.06% | 22.70pp |
| EPS | 16.85 | 105.5% |
Astec Lifesciences Reports 30.3% Increase in Consolidated Total Income in Q1FY26
28 Jul 2025 · 28 Jul 2025, 08:19 pm
Summary
Astec Lifesciences Limited has announced its financial results for the first quarter ended June 30, 2025. The company reported a consolidated total income of Rs. 91.6 crore in Q1FY26, a 30.3% increase over Q1FY25. The consolidated EBITDA loss was Rs. 10.5 crore in Q1FY26 compared to a loss of Rs. 45.3 crore in the same period last year.
Key Highlights
- 1
Consolidated total income increased by 30.3% in Q1FY26 over Q1 FY25
- 2
Consolidated EBITDA loss reduced to Rs. 10.5 crore in Q1FY26 from Rs. 45.3 crore in Q1 FY25
- 3
Net Profit after Tax (PAT) was Rs. (33.0) crore in Q1FY26 compared to Rs. (39.7) crore in Q1 FY25
- 4
Revenue in enterprise & CDMO businesses increased year on year by 68.2% & 85.7% respectively
Management Comments
Mr. N B Godrej
Astec reported improvement in performance on a year on year basis on the back of improvement in volumes & contribution in its enterprise business. Revenue in enterprise & CDMO businesses increased year on year by 68.2% & 85.7% respectively.
Informational and educational content only. Not investment advice.